:::

詳目顯示

回上一頁
題名:影響精神分裂症急性住院患者藥費之因素
書刊名:臺灣精神醫學
作者:張國榮蔡孟岳李文貴
作者(外文):Chang, Kao-jungTsai, Meng-yuehLee, Wen-kuei
出版日期:2004
卷期:18:3
頁次:頁216-223
主題關鍵詞:精神分裂症藥費精神科醫師抗精神病藥物SchizophreniaMedication costPsychiatristAntipsychotics
原始連結:連回原系統網址new window
相關次數:
  • 被引用次數被引用次數:期刊(0) 博士論文(0) 專書(0) 專書論文(0)
  • 排除自我引用排除自我引用:0
  • 共同引用共同引用:3
  • 點閱點閱:29
期刊論文
1.葉玲玲、藍忠孚、鄭若瑟(20030600)。臺灣精神分裂症患者精神醫療利用與費用之分析探討。臺灣公共衛生雜誌,22(3),194-203。new window  延伸查詢new window
2.Loosbrock, D. L.、Zhao, Z.、Johnstone, B. M.、Morris, L. S.(2003)。Antipsychotic medication use patterns and associated costs of care for individuals with schizophrenia。The Journal of Mental Health Policy and Economics,6,67-75。  new window
3.Martin, A.、Leslie, D.(2003)。Trends in psychotropic medication costs for children and adolescents, 1997-2000。Archives of Pediatrics & Adolescent Medicine,157,997-1004。  new window
4.Nasrallah, H. A.、Tandon, R.(2002)。Efficacy, safety, and tolerability of quetipine in patient with schizophrenia。The Journal of Clinical Psychiatry,63,12-20。  new window
5.Knapp, M.、Kavanagh, S.(1997)。Economic outcomes and costs in the treatment of schizophrenia。Clinical Therapeutics,19,128-138。  new window
6.Tunis, S. L.、Ascher-Svanum, H.、Stensland, M.、Kinon, B. J.(2004)。Assessing the value of antipsychotics for treating schizophrenia: the important of evaluation and interpreting the clinical significance of individual service costs。Pharmacoeconomics,22,1-8。  new window
7.Clark, R. E.、Bartels, S. J.、Mellman, T. A.、Peacock, W. J.(2002)。Recent trends in antipsychotic combination therapy of schizophrenia and schizosffective disorder: implications for state mental health policy。Schizophrenia Bulletin,28,75-84。  new window
8.Domino, M. E.、Frank, R. G.、Rosenheck, R.(2003)。The diffusion of new antipsychotic medications and formulary policy。Schizophrenia Bulletin,95-104。  new window
9.Bloom, J. R.、Cheng, J. S.、Hu, T. W.、Kang, S. H.、Wallace, N.(2003)。Use of antipsychotic medications in treating schizophrenia among different financing and delivery systems。The Journal of Mental Health Policy and Economics,6,163-171。  new window
10.Chong, M. Y.、Tan, C. H.、Fujii, S.(2004)。Antipsychotic drug prescription for schizophrenia in East Asia: rational for change。Psychiatry and Clinical Neurosciences,58,61-67。  new window
11.Hamann, J.、Leucht, S.、Kissling, W.(2003)。Are the second-generation antipsychotics cost-effective? A critical review on the background of different health systems。Pharmacopsychiatry,36,18-26。  new window
12.Mark, T. L.、Dirani, R.、Slade, E.、Russo, P. A.(2002)。Access to new medications to treat schizophrenia。The Journal of Behavioral Health Services & Research,29,15-29。  new window
13.Ganguli, G.(2003)。Consumers devise drug cost-cutting measures; medical and legal issues to consider。Health Care Manager,22,275-281。  new window
14.Martin, B. C.、Miller, L. S.、Kotzan, J. A.(2001)。Antipsychotic prescription use and costs for forecast。Schizophrenia Research,47,281-292。  new window
15.Gibson, P. J.、Damler, R.、Jackson, E. A.、Wilder, T.、Ramsey, J. L.(2004)。The impact of olanzapine, risperidone, or haloperiodol on the cost of schizophrenia care in a Medicaid population。Value Health,7,22-35。  new window
會議論文
1.鄭若瑟(2002)。臺灣精神障礙者照顧之現況分析與未來展-醫療層面。沒有紀錄。  延伸查詢new window
研究報告
1.(1995)。精神病患醫療服務體系之檢討。臺北市。  延伸查詢new window
圖書
1.陳美月(2001)。管理會計-規劃、控制與決策觀念。管理會計-規劃、控制與決策觀念。臺北市。  延伸查詢new window
其他
1.行政院衛生署(2000)。醫療網第四期計畫--新世紀健康照護計畫,行政院衛生署。  延伸查詢new window
2.(2003)。行政院衛生署健保字第0920066458號函:全民健康保險醫療給付費用總額及其分配,沒有紀錄。  延伸查詢new window
 
 
 
 
第一頁 上一頁 下一頁 最後一頁 top